Solution integrates both non-invasive ventilation (NIV) and high flow therapy (HFT) in a single device
Royal Philips’ V60 Plus ventilator has received CE mark approval, it was announced this week.
This comprehensive solution expands on Philips’ non-invasive ventilation (NIV) gold standard platform, integrating both NIV and high flow therapy (HFT) in a single device.
Now, clinicians can rapidly adjust therapies around constantly-changing patient conditions without having to switch devices.
Designed for early intervention in respiratory failure, the V60 Plus enables clinicians to further enhance patient outcomes with less-invasive respiratory care therapies, while improving clinician workflow and maximising equipment investments.
Patients with acute respiratory failure require immediate attention from caregivers.
While early implementation with NIV is associated with less endotracheal intubation, as well as the reduction of serious complications and adverse events in the ICU, clinicians sometimes face challenges when weaning patients off of this therapy.
The V60 Plus now delivers a wide range of non-invasive support for these patients, which helps clinicians to begin the weaning process sooner.
Clinicians can now rapidly adjust therapies around changing patient conditions
“When treating respiratory patients in intensive and emergency care settings, it’s critical for clinicians to be able to wean efficiently or to quickly escalate care depending on their patient’s condition and specific needs. This often means complex workflows and alternating devices in time-sensitive situations,” said Jim Alwan, business leader of Philips Hospital Respiratory Care.
“We are excited to offer a comprehensive non-invasive solution that enables quick therapy and interface transitions, so clinicians can focus on providing for their patients while spending less time setting up equipment.”